OXBR vs. RDZN, NEUE, HIT, AAME, ZBAO, HUIZ, FGF, AIFU, CNFR, and TIRX
Should you be buying Oxbridge Re stock or one of its competitors? The main competitors of Oxbridge Re include Roadzen (RDZN), NeueHealth (NEUE), Health In Tech (HIT), Atlantic American (AAME), Zhibao Technology (ZBAO), Huize (HUIZ), Fundamental Global (FGF), AIFU (AIFU), Conifer (CNFR), and Tian Ruixiang (TIRX). These companies are all part of the "insurance" industry.
Oxbridge Re vs. Its Competitors
Roadzen (NASDAQ:RDZN) and Oxbridge Re (NASDAQ:OXBR) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.
Oxbridge Re has a net margin of -143.80% compared to Roadzen's net margin of -164.51%. Roadzen's return on equity of 0.00% beat Oxbridge Re's return on equity.
In the previous week, Roadzen had 2 more articles in the media than Oxbridge Re. MarketBeat recorded 6 mentions for Roadzen and 4 mentions for Oxbridge Re. Roadzen's average media sentiment score of 1.29 beat Oxbridge Re's score of 0.47 indicating that Roadzen is being referred to more favorably in the media.
24.7% of Roadzen shares are held by institutional investors. Comparatively, 5.6% of Oxbridge Re shares are held by institutional investors. 26.8% of Roadzen shares are held by insiders. Comparatively, 15.3% of Oxbridge Re shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Oxbridge Re has lower revenue, but higher earnings than Roadzen. Oxbridge Re is trading at a lower price-to-earnings ratio than Roadzen, indicating that it is currently the more affordable of the two stocks.
Roadzen has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Oxbridge Re has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
Roadzen presently has a consensus target price of $5.00, indicating a potential upside of 419.21%. Oxbridge Re has a consensus target price of $5.00, indicating a potential upside of 121.73%. Given Roadzen's higher possible upside, research analysts plainly believe Roadzen is more favorable than Oxbridge Re.
Summary
Roadzen beats Oxbridge Re on 9 of the 15 factors compared between the two stocks.
Get Oxbridge Re News Delivered to You Automatically
Sign up to receive the latest news and ratings for OXBR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OXBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxbridge Re Competitors List
Related Companies and Tools
This page (NASDAQ:OXBR) was last updated on 7/16/2025 by MarketBeat.com Staff
Free OXBR Stock Alerts